Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for GVHD patients: nilotinib steps in when imatinib fails

NCT ID NCT02891395

Completed Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug nilotinib in 65 adults with chronic graft-versus-host disease (GVHD) who did not respond to imatinib. GVHD is a complication after a stem cell transplant where donor cells attack the patient's body. The goal was to see if nilotinib could help control the disease. Participants were followed for up to 52 weeks to measure response rates and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nilotinib
What this could lead to
If successful, nilotinib could offer a new treatment option for chronic GVHD patients who have not responded to imatinib.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 65 participants. Results may not apply to all patients, and nilotinib may cause side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT-VERSUS-HOST DISEASE

Contacts and locations

Locations

  • CHU Besançon

    Besançon, France

  • CHU Bordeaux

    Bordeaux, France

  • CHU Clémenceau

    Caen, France

  • CHU Grenoble

    Grenoble, France

  • CHU Hotel Dieu

    Nantes, France

  • CHU Purpan

    Toulouse, France

  • CHU Sart Tilman

    Liège, Belgium

  • CHU d'Amiens

    Amiens, France

  • CHU d'Angers

    Angers, France

  • CHU de Clermont Ferrand

    Clermont-Ferrand, France

  • CHU de Lyon

    Lyon, France

  • CHU de Nice

    Nice, France

  • CHU de STRASBOURG

    Strasbourg, France

  • Centre Henri Becquerel

    Rouen, France

  • Centre hospitalier et régional de Lille

    Lille, France

  • Diseases of Blood Service HURIEZ hospital CHRU de LILLE

    Lille, 59037, France

  • HIA de Percy

    Clamart, France

  • Hopital Morvan

    Brest, France

  • Hopital NECKER

    Paris, France

  • Hôpital Saint Eloi

    Montpellier, France

  • Hôpital pitié Salpetrière

    Paris, France

  • Institut Paoli Calmettes

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.